284 results
DAPT-SHOCK-AMI trial: Cangrelor in cardiogenic shock
03 Sep 2025
Kalaivani Mahadevan and Fizzah Choudry provide their take on DAPT-SHOCK-MI presented by Zuzana Motovska at ESC Congress 2025 in Madrid.
Author
Author
Optical coherence tomography- vs angiography-guided coronary stent implantation in calcified lesions: the ILUMIEN IV trial
28 Aug 2025
In the overall population (n = 2,114), there was a significant interaction between the effect of randomisation to OCT guidance vs angiography guidance in lesions with moderate/severe calcification (n = 1,082) vs no/mild calcification (n = 1,032) on the 2-year rate of TVF (Pinteraction = 0.01).
Reviewer
TACSI: Dual or single antiplatelet therapy after CABG in patients with acute coronary syndrome
03 Sep 2025
Aaysha Cader provides her take on TACSI presented by Anders Jeppsson at ESC Congress 2025 in Madrid.
Author
NEO-MINDSET: Early withdrawal of aspirin after percutaneous coronary intervention for acute coronary syndrome
02 Sep 2025
Daniele Giacoppo reports and provides his perspective on the main results of the ambitious NEOMINDSET trial, presented by Pedro Lemos from the Hospital Israelita Albert Einstein, São Paulo, Brazil, during a Late Breaking Trials session at the ESC Congress 2025 in Madrid, and simultaneously published in the New...
Author
Duration of DAPT in ACS: The DUAL-ACS Trial
31 Aug 2025
Ali Nazmi Calik interviews David Newby on the landmark DUAL-ACS trial results he presented at ESC Congress 2025 in Madrid.
The trial compared 3 months versus 12 months of dual antiplatelet therapy (DAPT) after myocardial infarction in an all-comer population. Findings suggest that shorter therapy may offer better...
Author
Author
One- versus three-month DAPT after everolimus-eluting stent implantation in diabetic patients at high-bleeding risk: results from the XIENCE Short DAPT programme
17 Jun 2025
This analysis from the XIENCE Short DAPT programme compared the safety and efficacy of one-month versus three-month DAPT in high-bleeding risk patients with and without diabetes mellitus (DM) following PCI with everolimus eluting stents (EES).
Reviewer
Outcomes after CABG compared with FFR-guided PCI in patients presenting with acute coronary syndrome
10 Jun 2025
This prespecified analysis of the Fractional Flow Reserve versus Angiography for Multivessel Evaluation (FAME 3) trial examined the impact on cardiovascular outcomes of treatment by CABG versus FFR-guided PCI in patients with three vessel disease (3-VD), stratified by acute (NSTEMI) or chronic coronary syndrome (CCS) presentation.
Reviewer
Reviewer
Recurrent events analysis of MASTER DAPT: total ischemic and bleeding events after abbreviated vs prolonged DAPT in HBR patient
04 Jun 2025
This exploratory analysis from the MASTER DAPT trial evaluates the effect of abbreviated versus prolonged DAPT on total ischaemic and bleeding events in high-bleeding-risk patients from the MASTER DAPT trial.
Reviewer
Overcoming complex anatomy in NSTEMI
23 May 2025 – From EuroPCR 2025
Explore advanced interventional strategies addressing complex anatomy in NSTEMI patients. This session presents challenging cases including unusual STEMI presentations with cardiogenic shock in Takayasu arteritis, subtotal aorto-ostial lesions in young patients, and management of giant coronary artery aneurysms, emphasizing tailored approaches to optimize outcomes.
How coronary physiology may help in guiding treatment of NSTEMI
23 May 2025 – From EuroPCR 2025
This session explores the utility of coronary physiology in guiding NSTEMI treatment. Topics include ischemia with non-obstructive arteries, QFR quality assessment, FFR-CT impact, revascularization deferral, and sex differences in FFR-guided strategies for acute myocardial infarction with multivessel disease.
Risk stratification of NSTEMI patients
22 May 2025 – From EuroPCR 2025
Explore the latest insights on risk stratification in NSTEMI patients through comparative analysis of established risk scores such as GRACE, HEART, and TIMI in predicting coronary artery disease severity. This session also reviews outcomes based on diabetes status and left ventricular ejection fraction, prospective validation of...
Calcified un-dilatable lesions in ACS: what should I do?
22 May 2025 – From EuroPCR 2025
Address the challenges of severely calcified undilatable lesions during acute coronary syndrome PCI. This session reviews the impact of coronary calcification on PCI strategy, highlights pitfalls in lesion preparation, and presents detailed case studies demonstrating effective treatment approaches.
Bifurcation CAD: presentation and PCI strategies
22 May 2025 – From EuroPCR 2025
Navigate the complexities of coronary bifurcation disease with a comprehensive session covering decision-making, imaging applications, and PCI strategies. Review clinical scenarios involving left main disease, calcifications, and acute presentations. Understand the pivotal role of intracoronary imaging and explore provisional and two-stent techniques through detailed case discussions...
Challenging left main PCI in NSTEMI patients
22 May 2025 – From EuroPCR 2025
Address the complexities of left main PCI in NSTEMI patients with challenging clinical presentations. This session discusses management of complex left main bifurcation disease, early graft failure guided by imaging and physiology, revascularization strategies for coronary left main occlusion, PCI complications requiring CTO techniques, and acute...
Managing ischaemic and bleeding risk of NSTEMI patients
22 May 2025 – From EuroPCR 2025
Gain valuable insights into managing ischemic and bleeding risks in NSTEMI patients. This session reviews optimal timing for invasive strategies, variability in care processes, radial access approaches, and innovative antithrombotic strategies such as aspirin omission and prasugrel monotherapy to minimize bleeding while optimizing outcomes.
Spotlight on major Late-Breaking Trials presented at EuroPCR 2025
21 May 2025
These trials were selected because of their design, results, and potential to impact practice: Discover the key findings of the 4D-ACS and FAITAVI randomised clinical trials and a meta-analysis of PROTECTED TAVR and BHF PROTECT TAVI.
Imaging-guided management of PCI pitfalls in NSTEMI
21 May 2025 – From EuroPCR 2025
Dive into the imaging-guided management of PCI pitfalls in NSTEMI patients. This session highlights critical cases such as complications from missed PCI, crushed stents, multiple coronary lumens, and migrating thrombus, emphasizing the role of advanced intracoronary imaging for precise diagnosis and optimized interventional outcomes.
Overcoming resistant lesions in NSTEMI
21 May 2025 – From EuroPCR 2025
Address the challenges of resistant lesions in NSTEMI with this focused session. Learn from complex cases involving thrombus management using Penumbra systems and Guideliner, as well as strategies to overcome extensive calcification through multiple interventional tools, illustrating a stepwise approach to tackling difficult coronary lesions.
Improving outcomes of NSTEMI patients
21 May 2025 – From EuroPCR 2025
Review contemporary evidence on improving outcomes for NSTEMI patients. Topics include the effects of evolocumab on stent coverage, impact of left ventricular function with kidney disease, GRACE score-based outcomes, PCI timing, and early initiation of Tafolecimab.
Complications management in NSTEMI patients
21 May 2025 – From EuroPCR 2025
Explore effective management strategies for complications in NSTEMI patients through real-life complex cases. Topics include saphenous vein graft stenting challenges, dislodged stents, rare coronary bifurcation perforations, and solutions for graft blockage with covered stents.
